Global HIV Vaccine Enterprise steering committees
Enterprise Advisory Group
The Global HIV Vaccine Enterprise Advisory Group (EAG) was established in 2019. It provides strategic and scientific advice on Enterprise activities that best meet the needs of the HIV vaccine research and development field and enable partnerships to deliver on the objectives of the Enterprise.
The EAG is made up of eight to 12 members with deep knowledge of, and strong connections across, the HIV vaccine field. The EAG reflects both gender and geographic diversity and includes civil society and community representatives.
Technical Working Group
The Technical Working Group (TWG) was established in February 2023. It aids the Enterprise in delivering on its work plan of activities by providing technical guidance and facilitating partnerships for the delivery of activities.
The TWG does this by:
- Advising the Enterprise team on the design of specific activities to deliver against the thematic work plan priorities identified by the Enterprise Advisory Group
- Supporting the identification of suitable collaborators in the delivery of these activities
- Proposing thematic priorities for consideration in upcoming work plans
Meet the members:
EU Vaccine Reference Group
The EU Vaccine Reference group was established in October 2022. It is made up of around 20 scientists from France, Germany, Italy, Switzerland, Spain, Sweden and other countries.
AIM: Support the development of an HIV vaccine by identifying and addressing barriers to effective R&D at the European level and influence priority settings for the next EU research programme and funding opportunities.
Meet the co-chairs:
